Precision Medicine Co.'s ASM Treatment Drug Gaining Rapid Market Adoption
Source: Streetwise Reports  (11/3/21)
Wedbush Securities Inc. advised that global precision therapy company Blueprint Medicines Corp.'s therapeutic AYVAKIT is gaining traction in patients diagnosed with advanced systemic mastocytosis and gastrointestinal stromal tumors. Wedbush reiterated its Outperform rating for the company and raised its 12-month price target by $4.00 to $136.00 per share. More >

Psychedelic Drug Trials Accelerate as Decriminalization Spreads, Investment Expands
Source: McAlinden Research for Streetwise Reports  (11/3/21)
McAlinden Research Partners estimates it may be only a matter of time before psychedelics become part of a biotech boom. More >

SLT Company's 'Cell Replacement in a Bottle' a Powerful Option in Treating Genetic Diseases
Source: Streetwise Reports  (11/2/21)
BTIG commented in a research report that Sigilon Therapeutics is developing a powerful and widely applicable "cell replacement in a bottle" as a potential functional cure for genetic diseases. BTIG advised it is initiating coverage on the company with a "Buy" rating and $14/share price target. More >

Diversified Bio-Pharma Firm Gains FDA Approval for Adrenocorticotropic Hormone Gel for Multiple Indications
Source: Streetwise Reports  (11/1/21)
Shares of ANI Pharmaceuticals Inc. traded 50% higher after the company reported the U.S. FDA approved its Purified Cortrophin Gel for use in treating multiple sclerosis, rheumatoid arthritis and nephrotic syndrome. More >

Medpace Shares Rise 13% on Higher Q3 Earnings & Forward Outlook
Source: Streetwise Reports  (10/26/21)
Shares of Medpace Holdings Inc. climbed to a new 52-week high after the CRO, a provider of full-service clinical trial development services, reported financial results for Q3/21 that included a 28.3% increase in YoY revenue. More >

Global Distribution Deal for Antibiotic Alternative for Livestock ‘Could Be a Game Changer’
Source: Streetwise Reports  (10/25/21)
Analyst David Bautz at Zacks Small-Cap Research wrote bullishly on Avivagen's eight-year distribution deal targeting the U.S., Brazil, and Thailand in an Oct. 11 report: The AB Vista deal “could be a game changer for the company as Avivagen now has a global partner that gives immediate credibility to the OxC-beta technology." More >

Radius Health Reports Positive Topline Data from Ph. 3 Metastatic Breast Cancer Trial
Source: Streetwise Reports  (10/20/21)
Shares of Radius Health Inc. traded 17% higher after the firm reported positive topline results from the Phase 3 EMERALD study of elacestrant in ER+/HER2- advanced or metastatic breast cancer (mBC). More >

Aquaculture Firm to Provide US Gulf Coast Distributor with 25,000 Pounds of Live Gourmet-Quality Shrimp
Source: Streetwise Reports  (10/19/21)
NaturalShrimp Inc.'s shares traded 12% higher after the company reported it entered into an agreement with Gulf Seafood Inc. for delivery of 25,000 lbs. of naturally grown, chemical and antibiotic-free, live shrimp. More >

New French Vaccine May 'Play an Important Role in Overcoming' COVID-19
Source: Streetwise Reports  (10/18/21)
Valneva SE shares traded 40% higher after the company reported positive results from its Phase 3 clinical trial of its COVID-19 vaccine candidate, VLA2001. The firm claimed that VLA2001 produced superior neutralizing antibody titer levels compared to AstraZeneca's AZD1222 (ChAdOx1-S) vaccine in the study. More >

Pacira Bids to Acquire Flexion to Expand Leadership Position in Non-Opioid Pain Management
Source: Streetwise Reports  (10/11/21)
Flexion Therapeutics Inc. shares traded 60% higher after the company reported it entered into a definitive agreement to be acquired by Pacira BioSciences Inc. for $8.00 per share in cash plus an additional non-tradeable contingent value right worth up to $8.00 per share in cash if five specific milestones are met. More >

ChemoCentryx Shares Double After FDA Approves TAVNEOSâ„¢ for Treatment of ANCA-Associated Vasculitis
Source: Streetwise Reports  (10/10/21)
Shares of ChemoCentryx Inc. traded 96% higher after the company reported the U.S. FDA approved its orally administered TAVNEOSâ„¢ (avacopan) for use in treatment of ANCA-associated vasculitis, a systemic autoimmune disease that often results in kidney or other major organ damage and failure that can be fatal if left untreated. More >

Merus Shares Rise 37% After Firm Presents Multiclonic Antibodies Clinical Data to Molecular Targets & Cancer Therapeutics Summit
Source: Streetwise Reports  (10/7/21)
Shares of Dutch oncology company Merus NV traded higher after the firm presented early and preclinical data for two full-length, multispecific antibodies, MCLA-158 and zenocutuzumab, to the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. More >

Voyager Shares Lift Off After Firm Signs License Deal With Pfizer for Next-Gen AAV Capsids for Gene Therapy Programs
Source: Streetwise Reports  (10/6/21)
Shares of Voyager Therapeutics Inc. traded 51% higher after the company reported it entered into a license and option agreement with Pfizer Inc. for two of its TRACERᵀᴹ AAV capsids that will be utilized to enhance Pfizer's neurologic and cardiovascular gene therapy programs. Voyager will receive an upfront payment of $30 million and is eligible to receive up to $600 million more plus product sales-based royalties, if all options are exercised and certain milestones are achieved. More >

Xenon Pharma Shares Gain 80% on Positive Data in Phase 2b Focal Epilepsy Trial
Source: Streetwise Reports  (10/4/21)
Shares of Xenon Pharmaceuticals Inc. soared to a new 52-week high after the company reported topline data from its Phase 2b X-TOLE clinical study demonstrating that its epilepsy drug candidate XEN1101 successfully met several primary and secondary efficacy endpoints and decreased monthly focal seizure frequency by 50% or greater from baseline. More >

Merck and Ridgeback Post Interim Data From Phase 3 Antiviral Drug Trial Showing 50% Reductions in Hospitalizations and Deaths in Mild and Moderate COV
Source: Streetwise Reports  (10/3/21)
Shares of Merck & Co. Inc. traded 9% higher after the company reported that in a global Phase 3 clinical trial conducted together with its partner Ridgeback Biotherapeutics, oral antiviral molnupiravir reduced risk of hospitalization or death by 50% versus placebo in patients with mild or moderate COVID-19. Merck plans to submit an Emergency Use Authorization application to the U.S. FDA and if authorized it would make molnupiravir the first approved oral antiviral medicine for COVID-19. More >

Coverage Initiated on Nanomedicine Firm, Upside 'Potentially Significant' With Upcoming Trial Results
Source: Streetwise Reports  (10/1/21)
"With Clene's potential to realize several multibillion-dollar revenue opportunities, we see its roughly $480 million enterprise value as offering attractive risk-reward," an Oppenheimer report noted. More >

Alzamend Shares Rise After FDA Gives Positive Response to Pre-IND Filing for Immune-Boosting Alzheimer's Vaccine
Source: Streetwise Reports  (9/30/21)
Shares of Alzamend Neuro Inc. traded 36% higher after the company reported that the U.S. FDA responded favorably to its Pre-IND application for AL002, a cell-based therapeutic vaccine designed to restore patients' immunological systems, providing them with the ability to combat Alzheimer's Disease. The FDA has granted the firm approval to initiate a combined Phase 1/2 clinical trial in Q1/22.

More >

COVID-19 Vaccine Could Be Approved in Q4/21 for 5 to 11 Year Olds
Source: Streetwise Reports  (9/30/21)
"Label extension for BioNTech and Pfizer's Comirnaty [vaccine] to include use in these younger individuals ought to buoy revenue growth near term," noted an H.C. Wainwright & Co. report. More >

Biopharma Expands Clinical Program of Lead Drug Candidate to Treat Chronic Cough
Source: Streetwise Reports  (9/29/21)
Algernon Pharmaceuticals will now pursue Ifenprodil in chronic cough based on encouraging recent study results in a Phase 2 trial. More >

Nanotech Co.'s Shares Trade Higher After Developing Antimicrobial Coating for PPE
Source: Streetwise Reports  (9/23/21)
ZEN Graphene Solutions Ltd. shares traded 13.5% higher after the company reported it delivered its first revenue-generating shipment of ZENGuard, a patent-pending coating with 99% antimicrobial activity. The first commercial shipment follows the firm's announcement yesterday that Health Canada determined ZENGuard enhanced surgical masks are safe for use by Canadians. More >

Dynavax Shares Shoot Up 30% After Its Partner Clover Biopharma Met All Key Efficacy Endpoints in Ph. 2/3 COVID-19 Vaccine Trial
Source: Streetwise Reports  (9/22/21)
Shares of Dynavax Technologies Corp. established a new 52-week high after the company reported that in the global Phase 2/3 SPECTRA COVID-19 vaccine study its collaborative partner Clover Biopharmaceuticals met all primary and secondary efficacy endpoints. Clover's vaccine, which was developed using Dynavax's CpG 1018 adjuvant, demonstrated 100% efficacy against severe COVID-19 and 84% efficacy against moderate-to-severe COVID-19 caused by any strain of SARS-CoV-2, including the Delta, Gamma, and Mu variants. More >

'Poised for Two Key Readouts in Q1/22' as Biopharma Advances Pipeline
Source: Streetwise Reports  (9/21/21)
Rezolute's two drug candidates, one for congenital hyperinsulinism and the other for diabetic macular edema, are discussed in an H.C. Wainwright & Co. report. More >

Target Price Raised on Biopharma After It Acquires Company, Splits Stock
Source: Streetwise Reports  (9/20/21)
AzurRx BioPharma now has five additional shots on goal "with the imminent full acquisition of just one compound," a ROTH Capital Partners report noted. More >

Edessa Biotech Shares Rise 87% on Positive Findings in Phase 2 Monoclonal Antibody COVID-19 Study
Source: Streetwise Reports  (9/20/21)
Edesa Biotech Inc. shares reached a new 52-week high after the company reported positive results from its Phase 2/3 monoclonal antibody study in hospitalized COVID-19 patients. More >

Innate Pharma Shares Rise After AstraZeneca Presents Positive Data From NSCLC Trial to European Conference
Source: Streetwise Reports  (9/18/21)
Innate Pharma S.A. shares traded 38% higher after the company reported its development partner AstraZeneca Plc. reported positive interim results from its Phase 2 COAST Study to the European Society for Medical Oncology Congress. When taken together with durvalumab, monalizumab was shown to improve progression-free survival and objective response rates in patients with unresectable, Stage III non-small cell lung cancer. More >